


# Early Anticoagulation Reversal In Surgical & Trauma Patients



	warfarin	dabigatran	rivaroxaban	apixaban
Mechanism	Vit K antagonist	Direct Thrombin inhibitor	Factor Xa inhibitor	Factor Xa inhibitor
Renal metabolism	none	80-85%	35%	25%
Peak effect (h)	72-96	1-2	2-4	3-4
Half-life (h)	40	12-14	6-13	10-14
PT/INR	elevated	+/-	+/-	+/-
aPTT	+/-	elevated	+/-	+/-
Anti-Xa level			elevated	elevated
Test for presence or absence	PT/INR	Thrombin time*	Anti-Xa level**	Anti-Xa level**
Reversal agent (preferred)	4F-PCC	Idarucizumab	Andexanet alfa or 4F-PCC	Andexanet alfa or 4F-PCC

\* Thrombin time (not widely available) can exclude presence of dabigatran when normal.

\*\* Anti-Factor Xa level of zero indicates no clinically relevant anti-Xa agent is present.

Source: Peck KC, Ley EJ, Brown CV, et al. Early anticoagulation reversal after trauma: a Western Trauma Association critical decisions algorithm. J Trauma Acute Care Surgery. 2021; 90: 331-336.